Crohn’s Disease: A Literature Review of Clinical Manifestations, Diagnosis, Management, and Radiological Findings
DOI:
https://doi.org/10.58258/6mqzx194Abstract
Crohn’s disease is a chronic inflammatory bowel disease characterized by transmural and discontinuous inflammation of the gastrointestinal tract. Its diverse clinical manifestations and progressive course can pose challenges in diagnosis and management, while persistent inflammation can lead to strictures, fistulas, abscesses, and intestinal obstruction. This literature review aims to summarize the clinical manifestations, diagnosis, management, and radiological features of Crohn’s disease. Literature was retrieved from PubMed, Google Scholar, and ScienceDirect using keywords related to Crohn’s disease, inflammatory bowel disease, diagnosis, management, radiology, computed tomography enterography, and magnetic resonance enterography. English-language publications from 2019 to 2025 were selected based on their relevance to the topic. The review findings indicate that Crohn’s disease typically presents with diarrhea, abdominal pain, and weight loss. Diagnosis requires the integration of clinical, laboratory, endoscopic, histopathological, and imaging findings. Management focuses on controlling inflammation, achieving remission, preventing complications, and improving quality of life through individualized therapy and a treat-to-target approach. Radiological imaging plays a crucial role in assessing the extent, activity, and complications of the disease. Computed tomography enterography and magnetic resonance enterography can reveal intestinal wall thickening, increased contrast uptake in the intestinal wall, ulcers, strictures, fistulas, and abscesses. Overall, the integration of clinical and radiological assessments is essential to support accurate diagnosis, appropriate management, and long-term monitoring of Crohn’s disease.References
[1] H. N. Utami et al., “Crohn disease: Pathophysiology, diagnosis and management,” Lombok Medical Journal, vol. 2, no. 2, pp. 5–13, 2023.
[2] T. Qiao and X. H. Wen, “Exploring gut microbiota as a novel therapeutic target in Crohn’s disease: Insights and emerging strategies,” World Journal of Gastroenterology, vol. 31, no. 2, Art. no. 100827, 2025.
[3] J. Feuerstein and A. Cheifetz, “Crohn disease: Epidemiology, diagnosis, and management,” Mayo Clinic Proceedings, vol. 92, pp. 1088–1103, 2017, doi: 10.1016/j.mayocp.2017.04.010.
[4] K. Heydari et al., “Global prevalence and incidence of inflammatory bowel disease: A systematic review and meta-analysis of population-based studies,” Gastroenterology and Hepatology From Bed to Bench, vol. 18, pp. 132–146, 2025, doi: 10.22037/ghfbb.v18i2.3105.
[5] S. Ng et al., “Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies,” The Lancet, vol. 390, no. 10114, pp. 2769–2778, 2017, doi: 10.1016/S0140-6736(17)32448-0.
[6] M. Kuenzig et al., “Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: Systematic review,” Gastroenterology, 2022, doi: 10.1053/j.gastro.2021.12.282.
[7] A. Sáez, B. Herrero-Fernández, R. Gómez-Bris, H. Sánchez-Martinez, and J. González-Granado, “Pathophysiology of inflammatory bowel disease: Innate immune system,” International Journal of Molecular Sciences, vol. 24, 2023, doi: 10.3390/ijms24021526.
[8] B. M. Acosta et al., “Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn’s disease) in Spain: A systematic review,” Advances in Therapy, vol. 40, pp. 1975–2014, 2023, doi: 10.1007/s12325-023-02473-6.
[9] M. Gajendran, P. Loganathan, A. Catinella, and J. G. Hashash, “A comprehensive review and update on Crohn's disease,” Disease-a-Month, vol. 64, no. 2, pp. 20–57, 2018, doi: 10.1016/j.disamonth.2017.07.001.
[10] A. Varma et al., “Patient-reported impact of symptoms in Crohn's disease,” The American Journal of Gastroenterology, vol. 117, pp. 2033–2045, 2022, doi: 10.14309/ajg.0000000000001954.
[11] V. Calvez et al., “Novel insights into the pathogenesis of inflammatory bowel diseases,” Biomedicines, vol. 13, 2025, doi: 10.3390/biomedicines13020305.
[12] A. Mauduit, E. Mas, N. Solà-Tapias, S. Ménard, and F. Barreau, “Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: Involvement in gut inflammation,” Journal of Gastroenterology, vol. 60, pp. 1323–1338, 2025, doi: 10.1007/s00535-025-02289-x.
[13] D. Kúsulas-Delint et al., “Crohn’s disease. Review and current concepts,” Revista de Investigación Médica Sur, vol. 23, no. 1, pp. 10–20, 2016.
[14] G. Cicero and G. Mazziotti, “Crohn’s disease at radiological imaging: focus on techniques and intestinal tract,” Intestinal Research, vol. 19, no. 4, pp. 365–378, 2021, doi: 10.5217/ir.2020.00097
[15] S. Hong and D. Baek, “Diagnostic procedures for inflammatory bowel disease: Laboratory, endoscopy, pathology, imaging, and beyond,” Diagnostics, vol. 14, 2024, doi: 10.3390/diagnostics14131384.
[16] G. Roda et al., “Crohn’s disease,” Nature Reviews Disease Primers, vol. 6, pp. 1–19, 2020, doi: 10.1038/s41572-020-0156-2.
[17] E. Bretto, M. Urpì-Ferreruela, G. Casanova, and B. González-Suárez, “The role of gut microbiota in gastrointestinal immune homeostasis and inflammation: Implications for inflammatory bowel disease,” Biomedicines, vol. 13, 2025, doi: 10.3390/biomedicines13081807.
[19] J. G. Hashash, J. K. Limdi, J. M. Shapiro, and S. A. Shah, “Medical management of inflammatory bowel diseases,” BMJ, vol. 391, 2025, doi: 10.1136/bmj-2025-079050.
[20] L. Petagna et al., “Pathophysiology of Crohn’s disease inflammation and recurrence,” Biology Direct, vol. 15, 2020, doi: 10.1186/s13062-020-00280-5.
[21] M. Agrawal, E. Spencer, J. Colombel, and R. Ungaro, “Approach to the management of recently diagnosed inflammatory bowel disease patients: A user’s guide for adult and pediatric gastroenterologists,” Gastroenterology, vol. 161, pp. 47–65, 2021, doi: 10.1053/j.gastro.2021.04.063.
[22] K. M. Alula and A. L. Theiss, “Autophagy in Crohn’s disease: Converging on dysfunctional innate immunity,” Cells, vol. 12, 2023, doi: 10.3390/cells12131779.
[23] M. D. Kappelman et al., “Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population,” Digestive Diseases and Sciences, vol. 58, pp. 519–525, 2013, doi: 10.1007/s10620-012-2371-5.
[24] G. Ramos and K. Papadakis, “Mechanisms of disease: Inflammatory bowel diseases,” Mayo Clinic Proceedings, vol. 94, no. 1, pp. 155–165, 2019, doi: 10.1016/j.mayocp.2018.09.013.
[25] T. Akkoç, “Epithelial barrier dysfunction and microbial dysbiosis: Exploring the pathogenesis and therapeutic strategies for Crohn’s disease,” Tissue Barriers, vol. 13, 2024, doi: 10.1080/21688370.2024.2390705.
[26] E. Caparrós et al., “Dysbiotic microbiota interactions in Crohn’s disease,” Gut Microbes, vol. 13, 2021, doi: 10.1080/19490976.2021.1949096.
[27] J. Shen, S. Du, Y. Zhang, H. Li, X. Liu, and J. Jing, “Bidirectional crosstalk between intestinal epithelium and immune microenvironment in inflammatory bowel disease: Mechanisms and therapeutic implications,” Journal of Inflammation Research, vol. 19, 2026, doi: 10.2147/JIR.S538988.
[28] R. Rashed, R. Valcheva, and L. Dieleman, “Manipulation of gut microbiota as a key target for Crohn's disease,” Frontiers in Medicine, vol. 9, 2022, doi: 10.3389/fmed.2022.887044.
[29] B. Caron, S. Honap, and L. Peyrin-Biroulet, “Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies,” Journal of Crohn's & Colitis, vol. 18, pp. ii3–ii15, 2024, doi: 10.1093/ecco-jcc/jjae082.
[31] S. Moon et al., “Trends and risk factors of elderly-onset Crohn’s disease,” World Journal of Gastroenterology, vol. 26, no. 4, pp. 404–415, 2020.
[32] X. Xu, W. Li, T. Ling, X. Lan, Y. Wang, F. Yuan, and T. Zhang, “Combined endoscopic and radiologic approaches for differentiating inflammatory and fibrotic strictures in Crohn's disease: A comprehensive diagnostic strategy,” Journal of Clinical Gastroenterology, 2025, doi: 10.1097/MCG.0000000000002294.
[34] Y.-D. Wang, R.-N. Zhang, R. Mao, and X.-H. Li, “Inflammatory bowel disease cross-sectional imaging: What’s new?” United European Gastroenterology Journal, vol. 10, no. 10, pp. 1179–1193, 2022, doi: 10.1002/ueg2.12343.
[35] M. J. Pruijt et al., “Diagnostic accuracy of intestinal ultrasound in the detection of intra-abdominal complications in Crohn’s disease: A systematic review and meta-analysis,” Journal of Crohn’s and Colitis, vol. 18, no. 6, pp. 958–972, 2024.
[36] S. Kumar et al., “Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn’s disease,” Journal of Crohn’s and Colitis, vol. 18, no. 9, pp. 1450–1463, 2024.
[37] F. Maccioni et al., “Comprehensive imaging evaluation and staging of Crohn’s disease: When and why to use intestinal ultrasound, MRE, or CTE: Current guidelines and future directions,” Diagnostics, vol. 16, 2026, doi: 10.3390/diagnostics16060882.
[38] G. Losurdo et al., “Small intestinal contrast ultrasonography (SICUS) in Crohn’s disease: Systematic review and meta-analysis,” Journal of Clinical Medicine, vol. 12, 2023, doi: 10.3390/jcm12247714.
[39] E. Anand et al., “Current practice and innovations in diagnosing perianal fistulizing Crohn’s disease (pfCD): A narrative review,” Techniques in Coloproctology, vol. 29, 2025, doi: 10.1007/s10151-025-03122-6.
[40] C. Maaser et al., “ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications,” Journal of Crohn’s and Colitis, vol. 13, no. 2, pp. 144–164, 2019.
[41] S. Kedia et al., “Differentiating Crohn’s disease from intestinal tuberculosis,” World Journal of Gastroenterology, vol. 25, pp. 418–432, 2019, doi: 10.3748/wjg.v25.i4.418.
[42] A. Choudhury et al., “Differentiating gastrointestinal tuberculosis and Crohn's disease: A comprehensive review,” BMC Gastroenterology, vol. 23, 2023, doi: 10.1186/s12876-023-02887-0.
[43] S. Cazacu et al., “The overlap between Crohn’s disease and intestinal tuberculosis: A never-ending story,” Medicina, vol. 62, 2026, doi: 10.3390/medicina62040794.
[44] J. Yoo et al., “Clinical usefulness of immune profiling for differential diagnosis between Crohn’s disease, intestinal tuberculosis, and Behcet’s disease,” Diagnostics, vol. 13, 2023, doi: 10.3390/diagnostics13182904.
[45] H. Yang et al., “Computed tomography enterography increases the ability of endoscopy to differentiate Crohn’s disease from intestinal Behçet’s disease,” Frontiers in Medicine, vol. 9, 2022, doi: 10.3389/fmed.2022.900458.
[46] R. Feakins et al., “ECCO topical review on clinicopathological spectrum & differential diagnosis of IBD,” Journal of Crohn's & Colitis, 2021, doi: 10.1093/ecco-jcc/jjab141.
[47] H. Yang et al., “Differential diagnosis of Crohn’s disease and ulcerative primary intestinal lymphoma: A scoring model based on a multicenter study,” Frontiers in Oncology, vol. 12, 2022, doi: 10.3389/fonc.2022.856345.
[48] B. Veauthier and J. R. Hornecker, “Crohn’s disease: Diagnosis and management,” American Family Physician, vol. 98, no. 11, pp. 661–669, 2018.
[49] W. J. Sandborn, “Crohn’s disease evaluation and treatment: Clinical decision tool,” Gastroenterology, vol. 147, no. 3, pp. 702–705, 2014, doi: 10.1053/j.gastro.2014.07.022.
[50] L. Peyrin-Biroulet et al., “Defining disease severity in inflammatory bowel diseases: Current and future directions,” Clinical Gastroenterology and Hepatology, vol. 14, no. 3, pp. 348–354.e17, 2016, doi: 10.1016/j.cgh.2015.06.001.
Downloads
Published
Issue
Section
License
Authors who publish with Research of Service Administration Health and Sains Healthys agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.Â
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
